Infant Bacterial Therapeutics AB (publ)
Research Infant Bacterial Therapeutics AB (publ) (IBT-B) on Bullrun: market cap SEK 846.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIBT-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 846.01M
- Financial periodQ4 2025
- Net income-SEK 19.20M
- Free cash flow-SEK 20.09M
Valuation Snapshot
latest market cap is SEK 846.01M.
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
Frequently asked questions
What is Infant Bacterial Therapeutics AB (publ)'s market cap?
Infant Bacterial Therapeutics AB (publ)'s market capitalization is SEK 846.01M.
What does Infant Bacterial Therapeutics AB (publ) do?
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden.